Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Guggenheim lowered its price target on Intellia Therapeutics (NASDAQ:NTLA) to $14.00 from $45.00 on Wednesday, while maintaining a Buy rating on the gene editing company. According to InvestingPro data, the stock currently trades at $10.86, with analyst targets ranging from $7 to $106, reflecting the market’s divided outlook on this volatile biotech player.
The significant price target reduction reflects adjusted peak sales projections for Intellia’s key clinical programs. Guggenheim now models peak sales of approximately $330 million for NTLA-2002, down from a previous estimate of $380 million. InvestingPro analysis reveals the company’s current revenue stands at $52.86 million, with a concerning gross profit margin of -732.63%.
For NTLA-2001, the firm cut projected peak sales more dramatically to approximately $700 million from the prior estimate of $1.4 billion. Guggenheim also pushed back the anticipated launch date for NTLA-2001 from 2028 to 2030.
The revised price target is based on a 10-year risk-adjusted discounted cash flow analysis using a 12% discount rate and estimated fully diluted share count as of 2026. Guggenheim adjusted operating expense projections to align with management’s cash guidance, which should fund operations into 2027.
The firm anticipates additional dilution in 2026 and 2027 following MAGNITUDE-2 and HAELO Phase 3 readouts, and assigns an 80% probability of success for all clinical programs, noting that available data for the gene editing programs are predictive of final outcomes. While the company maintains a strong liquidity position with a current ratio of 5.19, InvestingPro analysis indicates rapid cash burn - a crucial factor for investors to monitor. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial analysis through our detailed Pro Research Report, available for over 1,400 US stocks.
In other recent news, Intellia Therapeutics reported its Q2 2025 earnings, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of -0.98, which was better than the forecasted -1.03, and generated revenue of $14.24 million, exceeding the anticipated $11.99 million. Following the earnings report, Wells Fargo adjusted its price target for Intellia Therapeutics from $50 to $45, maintaining an Overweight rating. This update was influenced by Intellia’s development timeline for its treatment, nex-z, targeting ATTR-PN, with enrollment in the MAGNITUDE-2 study expected to conclude in the first half of 2026. Additionally, Leerink Partners lowered their price target for the company from $42 to $41, while keeping an Outperform rating. This adjustment came after reviewing the company’s quarterly earnings and management commentary. These developments reflect ongoing evaluations by analysts in light of Intellia’s recent financial performance and strategic plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.